Search

Clinical Research

Author

clinicalresearchorganization

MEIRxRS provides staffing, recruiting and executive search for #Biotech #Pharma and #MedicalDevice companies.

How Allergan Continues to Make Drug Prices Insane

How Allergan Continues to Make Drug Prices Insane  BloombergQuintFull coverage https://www.bloombergquint.com/opinion/2018/01/09/how-allergan-continues-to-make-drug-prices-insane

Advertisements

HemaCare Announces OneBlood Exercises Second Investment Tranche Option

HemaCare Announces OneBlood Exercises Second Investment Tranche Option  Digital JournalFull coverage http://www.digitaljournal.com/pr/3614428

Allergan: 1000 Layoffs Prove Growth Is Dead

Allergan: 1000 Layoffs Prove Growth Is Dead  Seeking AlphaFull coverage https://seekingalpha.com/article/4135686-allergan-1000-layoffs-prove-growth-dead

MedMen Launches ‘Faces’ Cannabis Ad Campaign in California

MedMen Launches ‘Faces’ Cannabis Ad Campaign in California  GanjapreneurFull coverage https://www.ganjapreneur.com/medmen-launches-faces-cannabis-ad-campaign-in-california/

Medical Devices – ISO 13485 – Do You Really Know What You Need To? – Webinar

Medical Devices – ISO 13485 – Do You Really Know What You Need To? – Webinar  MilTechProcess Validation for Medical Devices – Statistical Approach – Webinar  satPRnews (press release)Full coverage http://www.military-technologies.net/2018/01/04/medical-devices-iso-13485-do-you-really-know-what-you-need-to-webinar/

Avelas Biosciences Broadens Management Team with Key Executive Additions

Avelas Biosciences Broadens Management Team with Key Executive Additions  NB HerardFull coverage https://nbherard.com/business/avelas-biosciences-broadens-management-team-with-key-executive-additions/48119

BRIEF-Pfenex Names Susan A. Knudson As Chief Financial Officer

BRIEF-Pfenex Names Susan A. Knudson As Chief Financial Officer  ReutersFull coverage https://www.reuters.com/article/brief-pfenex-names-susan-a-knudson-as-ch/brief-pfenex-names-susan-a-knudson-as-chief-financial-officer-idUSASB0BZQX

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary …

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary …  PR Newswire (press release)Full coverage https://www.prnewswire.com/news-releases/avelas-biosciences-completes-period-1-patient-enrollment-in-phase-2-study-of-avb-620-in-women-with-primary-nonrecurrent-breast-cancer-undergoing-surgery-300577505.html

Atara Starts Two Phase 3 Trials of Treatment for Lymphoma That Arises from a Transplant

Atara Starts Two Phase 3 Trials of Treatment for Lymphoma That Arises from a Transplant  Lymphoma News TodayFull coverage https://lymphomanewstoday.com/2018/01/04/atara-to-test-lymphoma-treatment-for-transplant-recipients-in-two-phase-3-trials/

Create a free website or blog at WordPress.com.

Up ↑

%d bloggers like this: